Why the study?
Does the use of non-aspirin NSAIDs increase the risk of cardiovascular events in patients requiring pain or inflammation relief?
Does the use of non-aspirin NSAIDs increase the risk of cardiovascular events in patients requiring pain or inflammation relief?
This position paper highlights the significant cardiovascular risks associated with non-aspirin NSAIDs, particularly COX-2 inhibitors and diclofenac, emphasizing the need for cautious use.
May warrant preferring naproxen over other non-aspirin NSAIDs in high-risk patients; extends RCT confirmation of differential cardiovascular safety.
No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2016) conducted a review in Pain, fever, and inflammation; cardiovascular risk. Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) was evaluated on Cardiovascular complications (thrombotic events, myocardial infarction, heart failure). Non-aspirin NSAIDs, particularly selective COX-2 inhibitors and diclofenac, are associated with an increased risk of cardiovascular complications, whereas naproxen appears to have the least risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: